Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • GENERAL HEALTH CARE NEWS—S.D.N.Y.: TV program critique of MCO and its CEO was not defamation
    • ADMINISTRATION OF FDC ACT—NOTICES: Importer of controlled substances application: CalCog Inc.
    • ADMINISTRATION OF FDC ACT—NOTICES: Protamine sulfate intravenous solution, 50 Milligrams/5 Milliliters, not withdrawn from sale
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—DAB DECISIONS: 5-year exclusion upheld in Medicaid fraud personal care billing scheme
    • COSMETICS—FINAL RULES: FDA expands list of permitted sunscreen ingredients
    • EXPERT INSIGHTS—Jurisdiction Under Scrutiny In OPO Challenge To 2020 Final Rule
    • FALSE CLAIMS ACT—D. Ariz.: Court denied in part motion to dismiss ENT health care center in a false claims action
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, ADMINISTRATION OF FDC ACT—NOTICES: Protamine sulfate intravenous solution, 50 Milligrams/5 Milliliters, not withdrawn from sale, (Jun 10, 2026)

    By WK Editorial Staff

    The drug products are no longer being marketed.

    The FDA determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. The determination means that FDA will not begin procedures to withdr ...

    By WK Editorial Staff

    The drug products are no longer being marketed.

    The FDA determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. The determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements (Notice, 91 FR 34634 (June 8, 2026)).

    Dates. June 5, 2026.

    FederalRegisterIssuances: Notices FDCActNews DrugBiologicNews PrescriptionDrugNews SafetyNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use